We’re developing the next generation of cancer immunotherapies using our modified oncolytic Vaccina virus technology to promote a durable anti-tumor response following systemic delivery.
We are advancing our promising pipeline of pre-clinical assets with best-in-class potential, toward the clinic.
“The VacV team is developing a pipeline of immunotherapies for cancer using a novel oncolytic Vaccinia virus technology based on over 20 years of ground-breaking research at one of the UK’s leading cancer research centers. Our enhanced systemic delivery platform addresses many of the historic challenges faced by oncolytic viruses and allows efficient targeting of tumor cells anywhere in the body.”